143 related articles for article (PubMed ID: 26761267)
1. Critical Review: Mechanisms of HIV Transmission in Depo-Provera Users: The Likely Role of Hypoestrogenism.
Hickey M; Marino JL; Tachedjian G
J Acquir Immune Defic Syndr; 2016 Jan; 71(1):1-7. PubMed ID: 26761267
[TBL] [Abstract][Full Text] [Related]
2. Forearm bone density in users of Depo-Provera as a contraceptive method.
Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
[TBL] [Abstract][Full Text] [Related]
3. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z
J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232
[TBL] [Abstract][Full Text] [Related]
4. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
[TBL] [Abstract][Full Text] [Related]
5. Progestin-based contraception regimens modulate expression of putative HIV risk factors in the vaginal epithelium of pig-tailed Macaques.
Bosinger SE; Tharp GK; Patel NB; Zhao C; Payne TL; Dietz Ostergaard S; Butler K; Ellis S; Johnson RL; Kersh EN; McNicholl JM; Vishwanathan SA
Am J Reprod Immunol; 2018 Oct; 80(4):e13029. PubMed ID: 30076667
[TBL] [Abstract][Full Text] [Related]
6. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety.
Westhoff C
Contraception; 2003 Aug; 68(2):75-87. PubMed ID: 12954518
[TBL] [Abstract][Full Text] [Related]
7. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
[TBL] [Abstract][Full Text] [Related]
8. Depot medroxyprogesterone acetate administration increases cervical CCR5+CD4+ T cells and induces immunosuppressive milieu at the cervicovaginal mucosa.
Tasker C; Pizutelli V; Lo Y; Ramratnam B; Roche NE; Chang TL
AIDS; 2020 Apr; 34(5):729-735. PubMed ID: 31972606
[TBL] [Abstract][Full Text] [Related]
9. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera.
Bahamondes L; Trevisan M; Andrade L; Marchi NM; Castro S; Díaz J; Faúndes A
Contraception; 2000 Jul; 62(1):23-7. PubMed ID: 11024225
[TBL] [Abstract][Full Text] [Related]
10. The contraceptive use of depot medroxyprogesterone acetate.
Hickey M; Fraser I
Clin Obstet Gynecol; 1995 Dec; 38(4):849-58. PubMed ID: 8616981
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera.
Kuhn L; Denny L; Pollack AE; Wright TC
Contraception; 1999 Jun; 59(6):363-7. PubMed ID: 10518230
[TBL] [Abstract][Full Text] [Related]
13. Depo-Provera and bone density.
Gbolade BA
J Fam Plann Reprod Health Care; 2002 Jan; 28(1):7-11; quiz 11, 50. PubMed ID: 16259806
[No Abstract] [Full Text] [Related]
14. Accounting for anovulation and vaginal thinning during depot medroxyprogesterone acetate use.
Atrio J
J Infect Dis; 2015 Mar; 211(5):850. PubMed ID: 25217405
[No Abstract] [Full Text] [Related]
15. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina.
Mostad SB; Overbaugh J; DeVange DM; Welch MJ; Chohan B; Mandaliya K; Nyange P; Martin HL; Ndinya-Achola J; Bwayo JJ; Kreiss JK
Lancet; 1997 Sep; 350(9082):922-7. PubMed ID: 9314871
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional response of vaginal epithelial cells to medroxyprogesterone acetate treatment results in decreased barrier integrity.
Woods MW; Zahoor MA; Lam J; Bagri P; Dupont H; Verschoor CP; Nazli A; Kaushic C
J Reprod Immunol; 2021 Feb; 143():103253. PubMed ID: 33285485
[TBL] [Abstract][Full Text] [Related]
17. Research gaps in defining the biological link between HIV risk and hormonal contraception.
Murphy K; Irvin SC; Herold BC
Am J Reprod Immunol; 2014 Aug; 72(2):228-35. PubMed ID: 24548147
[TBL] [Abstract][Full Text] [Related]
18. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
Polaneczky M; Liblanc M
J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
[TBL] [Abstract][Full Text] [Related]
19. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
[TBL] [Abstract][Full Text] [Related]
20. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
Potter LS; Dalberth BT; Cañamar R; Betz M
Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
